PTX 2.44% 4.2¢ prescient therapeutics limited

Interesting to read the response of clinicians regarding the...

  1. 7,791 Posts.
    lightbulb Created with Sketch. 3320
    Interesting to read the response of clinicians regarding the recent FDA review:-

    https://endpts.com/clinicians-say-benefits-of-car-t-continue-to-outweigh-risk-of-t-cell-malignancies/

    In it states the following:-

    The agency has not responded to requests for comment on how many CAR-positive T-cell malignancies were detected and the severity of the cases. Bishop noted that CAR-positive cases do not necessarily mean the patient’s cancer was caused by CAR-T treatment, and more information will be necessary to determine whether patients were predisposed to T-cell lymphomas.

    The fact that T-cell lymphomas is specifically mentioned, bodes extremely well for PTX-100.... the fact that it is a targeted therapy and not a Car-T therapy. Surely, the FDA will be more receptive to our upcoming submission.

 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.2¢
Change
0.001(2.44%)
Mkt cap ! $33.82M
Open High Low Value Volume
4.2¢ 4.3¢ 4.1¢ $23.91K 563.5K

Buyers (Bids)

No. Vol. Price($)
1 70733 4.2¢
 

Sellers (Offers)

Price($) Vol. No.
4.3¢ 24822 2
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.